title: The status of Her2 amplification and Kras mutations in mucinous ovarian carcinoma.
abstract: Jayson GC et al. remarked in Lancet that nearly 100% of mucinous ovarian cancer cases have Kras mutation as well as a high frequency of Her2 amplification. Using the Abbott PathVysion Her2 DNA Probe Kit and Kras mutant-enriched PCR Kits (FemtoPath®), 21 samples of primary ovarian mucinous cystadenocarcinomas from Taiwanese patients were examined to determine the status of Her2 amplification and Kras mutations. Our results showed the Her2 amplification rates were 33.33%, while the Kras mutation rates were 61.90%. We present here our results in order to enlighten the readership that the ~100% Kras mutant frequency and the high Her2 amplification rate reported by Jayson et al. may be too exaggerated to be applicable into all populations. Additionally, we report another 2 novel Kras mutations (A11V, V14I).
authors.affiliation: Department of Emergency Medicine, Chung-Shan Medical University and Chung Shan Medical University Hospital, Taichung, Taiwan.
authors.forename: Kuang-Leei
authors.initials: KL
authors.lastname: Chang
authors.affiliation: Department of Statistics and Informatics Science, Providence University, Taichung, Taiwan.
authors.forename: Ming-Yung
authors.initials: MY
authors.lastname: Lee
authors.affiliation: Department of Pathology, Chung-Shan Medical University and Chung Shan Medical University Hospital, Taichung, Taiwan. y1034@csmu.edu.tw.
authors.forename: Wan-Ru
authors.initials: WR
authors.lastname: Chao
authors.affiliation: Department of Pathology, Chung-Shan Medical University and Chung Shan Medical University Hospital, Taichung, Taiwan. cshy762@csh.org.tw.|Department of Obstetrics and Gynecology, Chung-Shan Medical University and Chung-Shan Medical University Hospital, No 110, Sec 1, Chien Kuo N. Rd, Taichung, 40201, Taiwan. cshy762@csh.org.tw.
authors.forename: Chih-Ping
authors.initials: CP
authors.lastname: Han
mesh_terms: D002288:Adenocarcinoma, Mucinous; D000077216:Carcinoma, Ovarian Epithelial; D005260:Female; D006801:Humans; D009154:Mutation; D010051:Ovarian Neoplasms; D016283:Proto-Oncogene Proteins p21(ras)
chemical_list: C117307:KRAS protein, human; D016283:Proto-Oncogene Proteins p21(ras)
keywords: Her2 amplification; Kras mutation; Mucinous ovarian carcinoma